Why the study?
Do postvaccination antibody titers correlate with protection against rotavirus infection or disease in subjects receiving a rotavirus vaccine?
Do postvaccination antibody titers correlate with protection against rotavirus infection or disease in subjects receiving a rotavirus vaccine?
Postvaccination rotavirus antibody titers show some correlation with protection against specific serotype illnesses, but no single titer serves as a reliable indicator of overall protection.
Answers are grounded in this paper and cite their sources.
Titers should not guide individual protection assessment; extends serotype-specific data but leaves reliable overall correlates unresolved.
The correlation of antibody responses (serum rotavirus IgA and neutralizing antibody to serotype G1-G4 human rotaviruses and rhesus rotavirus [RRV]) in a reassortant rotavirus vaccine trial with protection against rotavirus infection or disease was investigated. Most subjects administered 4 x 10(5) pfu of either the serotype G1 monovalent or serotype G1-G4 tetravalent vaccine seroconverted for at least one of the six antibodies (85% and 91%, respectively). However, fewer than one-third seroconverted to any prototype G1-G4 human rotavirus. Analyses of covariance indicated that higher prevaccination neutralizing antibody titers negatively affected postvaccination titers. Significant relationships were found between several postvaccination rotavirus antibody titers and protection, and serotype-specific correlates of protection were identified between anti-Wa titers and G1 illnesses (P = .03) and between anti-RRV titers and G3 illnesses (P < .001). Overall, however, serotype-specific immunity was no more significant than heterotypic immunity, and no specific titer of any antibody analyzed was a reliable indicator of protection.
No takes yet. Share an insight, caveat, or question.
Ward et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: